What Is New in Systemic Lupus Erythematosus

Larrinoa, Iñigo Rúa-Figueroa Fernández de

doi:10.1016/j.reumae.2014.09.001

Cited by 9 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic lupus erythematosus (SLE), the prototype of autoimmune diseases, is a highly heterogenous disease that affects all organ systems and has an unpredictable course [1]. Its course ranges from mild to severe or fatal disease [2].…”

Section: Introductionmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou

2023

Life

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects the outcome. Hydroxychloroquine should be administered to every lupus patient irrespective of organ involvement. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus. However, despite conventional immunosuppressive treatment, flares occur and broad immunosuppression is accompanied by multiple side effects. Flare occurrence, target organ involvement, side effects of broad immunosuppression and increased knowledge of the pathogenetic mechanisms involved in SLE pathogenesis as well as the availability of biologic agents has led to the application of biologic agents in SLE management. Biologic agents targeting various pathogenetic paths have been applied. B cell targeting agents have been used successfully. Belimumab, a B cell targeting agent, has been approved for the treatment of SLE. Rituximab, an anti-CD20 targeting agent is also used in SLE. Anifrolumab, an interferon I receptor-targeting agent has beneficial effects on SLE. In conclusion, biologic treatment is applied in SLE and should be further evaluated with the aim of a good treatment response and a significant improvement in quality of life.

show abstract

Section: Introductionmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou

2023

Life

View full text Add to dashboard Cite

show abstract

“…In the immunological dynamics of SLE, it seems that lupuzor favors the expansion of regulatory T cells to the detriment of effector ones. As a result, the lupuzor restores tolerance to nuclear autoantigens ( 3 ). A similar effect is observed in the case of vitamin D3 deficiency correction.…”

Section: Introductionmentioning

confidence: 99%

“…Correction of hypovitaminosis may also reduce cardiovascular risk and SLE activity. However, caution is required because of the risk of worsening lupus nephritis ( 3 – 5 ). Vitamin D3 is part of the group of fat-soluble secosteroid vitamins, having numerous implications in the body, among which we mention its role in cell growth, phospho-calcium balance, neuro-muscular activity and immunity.…”

Section: Introductionmentioning

confidence: 99%

The role of vitamin D in pediatric systemic lupus erythematosus - a double pawn in the immune and microbial balance

Lupu,

Jechel

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Having increased popularity during the Covid-19 pandemic, vitamin D3 is currently impressing thanks to the numerous researches aimed at its interactions with the body’s homeostasis. At the same time, there is a peak in terms of recommendations for supplementation with it. Some of the studies focus on the link between autoimmune diseases and nutritional deficiencies, especially vitamin D3. Since the specialized literature aimed at children (patients between 0-18 years old) is far from equal to the informational diversity of the adult-centered branch, this review aims to bring up to date the relationship between the microbial and nutritional balance and the activity of pediatric systemic lupus erythematosus (pSLE). The desired practical purpose resides in a better understanding and an adequate, individualized management of the affected persons to reduce morbidity. The center of the summary is to establish the impact of hypovitaminosis D in the development and evolution of pediatric lupus erythematosus. We will address aspects related to the two entities of the impact played by vitamin D3 in the pathophysiological cascade of lupus, but also the risk of toxicity and its effects when the deficiency is over supplemented (hypervitaminosis D). We will debate the relationship of hypovitaminosis D with the modulation of immune function, the potentiation of inflammatory processes, the increase of oxidative stress, the perfusion of cognitive brain areas, the seasonal incidence of SLE and its severity. Finally, we review current knowledge, post-pandemic, regarding the hypovitaminosis D – pSLE relationship.

show abstract

“…Systemic lupus erythematosus (SLE), the prototype of autoimmune diseases, is a highly heterogenous disease, affects all organ systems and has an unpredictable course [1]. Its course ranges from mild to severe fatal disease [2].…”

Section: Introductionmentioning

confidence: 99%

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Athanassiou¹,

Athanassiou²

2023

Preprint

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects the outcome. Hydroxychloroquine is the cornerstone of lupus treatment. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, azathioprine, cyclosporine and tacrolimus. Cyclophosphamide and mycophenolate mofetil may also be used. However, despite conventional immunosuppressive treatment flares occur and broad immunosuppression is accompanied by multiple side effects. Flare occurrence, target organ involvement, side effects of broad immunosuppression, increased knowledge of the pathogenetic mechanisms involved in SLE pathogenesis as well as the availability of biologic agents has led to the application of biologic agents in SLE management. Biologic agents targeting various pathogenetic paths have been applied. B cell targeting agents have been used successfully. Belimumab, a B cell targeting agent has been approved for the treatment of SLE. Rituximab, an anti-CD20 targeting agent is also used in SLE. Anifrolumab, an interferon I receptor targeting agent has beneficial effects on SLE. In conclusion, biologic treatment is applied in SLE and should be further evaluated with the aim of a good treatment response and a significant improvement in quality of life.

show abstract

What Is New in Systemic Lupus Erythematosus

Cited by 9 publications

References 28 publications

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

The role of vitamin D in pediatric systemic lupus erythematosus - a double pawn in the immune and microbial balance

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About